Ganetespib and Ziv-Aflibercept in Refractory Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and Sarcomas

NCT02192541 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

5

Enrollment

NIH

Sponsor class

Stopped Drug supplier suspended further clinical development of Ganetespib

Conditions

Neoplasms

Interventions

DRUG: Ziv-Aflibercept
DRUG: Ganetespib

Sponsor

National Cancer Institute (NCI)